Gleevec and Bleeding
During treatment with Gleevec® (imatinib mesylate), you may be at risk for abnormally low blood cell counts, such as low red blood cells, white blood cells, or platelets, which can increase your risk for anemia, infection, and bleeding problems.
Your healthcare provider will monitor your blood counts with a simple blood test every week for the first month you are taking Gleevec, every other week during the second month, and then periodically for the remainder of treatment. If you develop problems with bleeding, your healthcare provider may need to reduce your dose or temporarily stop treatment.
(To learn more about bleeding, edema, congestive heart failure, and other problems that may occur with this drug, click Gleevec Warnings and Precautions.)